Experimental Carboplatin & Paclitaxel With or Without Ramucirumab For Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Enter your info and the study team will contact you soon!
Your data is securely stored and only shared with the research team
Logo Image
"Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!"
Age: 18 years or older
Healthy Volunteers: No
Keywords: Thymic Carcinoma
Type: Drug study, Phase 2
6 Participants
The purpose of this study is to compare any good and bad effects of using experimental ramucirumab. It will be given along with the usual chemotherapy combination (carboplatin and paclitaxel).

Ramucirumab is FDA-approved for non-small cell lung cancer but not for thymic cancer. Ramucirumab in combination with carboplatin and paclitaxel is considered experimental.

Ramucirumab is a monoclonal antibody. It is a type of protein made in the laboratory that can bind to substances in the body, including cancer cells.

Ramucirumab targets the vascular endothelial growth factor receptor 2 (VEGFR 2). VEGFR2 is an important molecule that supports the growth of blood vessels by a process called angiogenesis. Growth of these blood vessels can feed tumors and cause them to grow. Ramucirumab blocks VEGFR2 and may prevent angiogenesis in advance thymic tumor patients.

This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the study approach should extend the amount of time you are cancer-free compared to the usual approach. This chemotherapy combination, carboplatin and paclitaxel, has already been FDA-approved.
This study requires

The study team will make sure you qualify to take part in the study. Qualified participants will receive detailed information about the study. This may include a list of study-related tests and procedures.

Who can participate

The study team will review the eligibility criteria with you.

Benefits and risks of participating

We cannot promise any benefits to you as a result of taking part in this research study.


The study doctor will discuss the risks associated with taking part in this research study.
You will not be paid to take part in this research study.
Study duration and period
You will receive the study treatment as long as your disease does not get worse and you are not having difficult side effects. After you finish the study treatment, we will follow-up with you for two years from the time you started the study.
Recruitment period
From March 8, 2019
UC Davis Comprehensive Cancer Center
4501 X Street
Sacramento, CA 95817
Research Topic
  • Locally Advanced Thymic Carcinoma
  • Metastatic Thymic Carcinoma
  • Recurrent Thymic Carcinoma
  • Unresectable Thymic Carcinoma

Have any questions or want to learn more? Leave your contact details below and the research team will reach out to you.


Send SMS with Study Info:

SMS Sent!

Share Study Info via Email:

E-mail Preview